Research identifies potential new treatment for sepsis

Sepsis is the leading cause of in-hospital death and there is no specific treatment for it. Now, research led by Dr. Qingping Feng of Western University (London, Canada) suggests a protein called recombinant human annexin A5 may have therapeutic potential for the treatment of this disease. The paper is published in advance, online in Critical Care Medicine.

Sepsis is caused by an overwhelming immune response to an existing infection. It's estimated there are 18 million cases annually worldwide. The mortality rate is 30 to 40 per cent for and 40 to 80 per cent for . Dr. Feng, a professor in the Departments of Physiology and Pharmacology, and Medicine at Western's Schulich School of Medicine & Dentistry and a scientist at Lawson Health Research Institute is particularly interested in how sepsis causes cardiac dysfunction.

Annexin A5 is a lipid-binding protein produced by cells. Using mice with induced sepsis, Dr. Feng, Dr. Xiangru Lu, and Paul Arnold, MSc, studied the effects of annexin A5 on cardiac function and animal survival.

"We treated the septic animals and to our surprise we found a dramatic, significant effect in improving cardiac function during sepsis and improved survival rates in the mice," says Dr. Feng. "We also found it helped even if administered hours after the septic infection. This is important because the delayed treatment simulates what usually happens in a clinical setting. The patient often has had sepsis for several hours, or a few days when they seek treatment."

Annexin A5 is not currently used as a therapeutic agent, but its safety has been tested in humans. It's currently used in imaging studies to identify cells undergoing apoptosis (cell death).

While this study looked at the heart, Dr. Feng believes annexin A5's beneficial properties could apply to multiple organs including liver, lungs and kidney, all which can all be affected by .

A patent for this discovery has been filed by WORLDiscoveries®. The Canadian Institutes of Health Research helped fund the research.

add to favorites email to friend print save as pdf

Related Stories

Study shows decrease in sepsis mortality rates

Nov 13, 2013

A recent study from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) shows a significant decrease in severe sepsis mortality rates over the past 20 years. Looking at data from patients with severe ...

Surviving sepsis with LECT2

Dec 17, 2012

Failure to launch an adequate immune response may be at the root of septic shock, according to a study published in The Journal of Experimental Medicine on December 17th.

Recommended for you

Growing a blood vessel in a week

1 hour ago

The technology for creating new tissues from stem cells has taken a giant leap forward. Three tablespoons of blood are all that is needed to grow a brand new blood vessel in just seven days. This is shown ...

Testing time for stem cells

4 hours ago

DefiniGEN is one of the first commercial opportunities to arise from Cambridge's expertise in stem cell research. Here, we look at some of the fundamental research that enables it to supply liver and pancreatic ...

Team finds key signaling pathway in cause of preeclampsia

23 hours ago

A team of researchers led by a Wayne State University School of Medicine associate professor of obstetrics and gynecology has published findings that provide novel insight into the cause of preeclampsia, the leading cause ...

Rapid test to diagnose severe sepsis

Oct 23, 2014

A new test, developed by University of British Columbia researchers, could help physicians predict within an hour if a patient will develop severe sepsis so they can begin treatment immediately.

User comments